Cargando…

Population Pharmacokinetic Modeling of Lucitanib in Patients with Advanced Cancer

BACKGROUND: Lucitanib is an oral, potent, selective inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors 1‒3, fibroblast growth factor receptors 1‒3, and platelet-derived growth factor receptors alpha/beta. OBJECTIVE: We aimed to develop a population pharmacokine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liao, Mingxiang, Zhou, Jie, Wride, Kenton, Lepley, Denise, Cameron, Terri, Sale, Mark, Xiao, Jim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399017/ https://www.ncbi.nlm.nih.gov/pubmed/35844029 http://dx.doi.org/10.1007/s13318-022-00773-w

Ejemplares similares

In Vitro and In Vivo Activity of Lucitanib in FGFR1/2 Amplified or Mutated Cancer Models()()
por: Guffanti, Federica, et al.
Publicado: (2016)

A Phase Ib Study of Lucitanib (AL3810) in a Cohort of Patients with Recurrent and Metastatic Nasopharyngeal Carcinoma
por: Zhang, Yang, et al.
Publicado: (2022)

Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib
por: Liao, Mingxiang, et al.
Publicado: (2022)

Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment
por: Grechko, Nikolay, et al.
Publicado: (2021)

Population pharmacokinetics and exposure–response modeling for evinacumab in homozygous familial hypercholesterolemia
por: Pu, Xia, et al.
Publicado: (2021)

Population pharmacokinetic modeling and simulations of berotralstat for prophylactic treatment of attacks of hereditary angioedema
por: Mathis, Amanda, et al.
Publicado: (2022)

Population Pharmacokinetic and Pharmacodynamic Modeling of LY2510924 in Patients With Advanced Cancer
por: Bihorel, S, et al.
Publicado: (2017)

Nonlinear Population Pharmacokinetics of Sirolimus in Patients With Advanced Cancer
por: Wu, K, et al.
Publicado: (2012)

Model‐based population pharmacokinetic analysis of tislelizumab in patients with advanced tumors
por: Budha, Nageshwar, et al.
Publicado: (2022)

Pharmacokinetic Models for FcRn-Mediated IgG Disposition
por: Xiao, Jim J.
Publicado: (2012)

Physiologically Based Pharmacokinetics Modeling in the Neonatal Population—Current Advances, Challenges, and Opportunities
por: Dinh, Jean, et al.
Publicado: (2023)

Population and Noncompartmental Pharmacokinetics of Sodium Oxybate Support Weight‐Based Dosing in Children and Adolescents With Narcolepsy With Cataplexy
por: Chen, Cuiping, et al.
Publicado: (2020)

Population pharmacokinetics of cabazitaxel in patients with advanced solid tumors
por: Ferron, Géraldine M., et al.
Publicado: (2013)

Population pharmacokinetic characteristics of cemiplimab in patients with advanced malignancies
por: Yang, Feng, et al.
Publicado: (2021)

Population Pharmacokinetics Analysis of Pemigatinib in Patients With Advanced Malignancies
por: Ji, Tao, et al.
Publicado: (2022)

Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab‐Treated Advanced Melanoma
por: Chatterjee, MS, et al.
Publicado: (2016)

Machine learning advances the integration of covariates in population pharmacokinetic models: Valproic acid as an example
por: Zhu, Xiuqing, et al.
Publicado: (2022)

Eccentric Exercise to Enhance Neuromuscular Control
por: Lepley, Lindsey K., et al.
Publicado: (2017)

Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors
por: Shapiro, Geoffrey I., et al.
Publicado: (2018)

Population pharmacokinetic modelling and simulation of fremanezumab in healthy subjects and patients with migraine
por: Fiedler‐Kelly, Jill B., et al.
Publicado: (2019)

Predictive Performance of Physiologically Based Pharmacokinetic and Population Pharmacokinetic Modeling of Renally Cleared Drugs in Children
por: Zhou, W, et al.
Publicado: (2016)

Deficits in Quadriceps Strength and Patient-Oriented Outcomes at Return to Activity After ACL Reconstruction: A Review of the Current Literature
por: Lepley, Lindsey K.
Publicado: (2015)

The Effect of Azithromycin on Ivermectin Pharmacokinetics—A Population Pharmacokinetic Model Analysis
por: El-Tahtawy, Ahmed, et al.
Publicado: (2008)

Population Pharmacokinetics of Nivolumab in Combination With Ipilimumab in Patients With Advanced Malignancies
por: Zhang, Jason, et al.
Publicado: (2019)

Population Pharmacokinetics and Exposure‐Safety Relationships of Alisertib in Children and Adolescents With Advanced Malignancies
por: Zhou, Xiaofei, et al.
Publicado: (2022)

Advanced knowledge in drug metabolism and pharmacokinetics
por: Yu, Ai-Ming, et al.
Publicado: (2016)

Population Pharmacokinetics of Pomalidomide
por: Li, Yan, et al.
Publicado: (2015)

Population Pharmacokinetic Modeling of Olaratumab, an Anti-PDGFRα Human Monoclonal Antibody, in Patients with Advanced and/or Metastatic Cancer
por: Mo, Gary, et al.
Publicado: (2017)

Population Pharmacokinetics of Oral Brepocitinib in Healthy Volunteers and Patients
por: Hughes, Jim H., et al.
Publicado: (2022)

Oseltamivir Population Pharmacokinetics in the Ferret: Model Application for Pharmacokinetic/Pharmacodynamic Study Design
por: Reddy, Micaela B., et al.
Publicado: (2015)

A Population Pharmacokinetic Modelling Approach to Unravel the Complex Pharmacokinetics of Vincristine in Children
por: Nijstad, A. Laura, et al.
Publicado: (2022)

Corticospinal tract structure and excitability in patients with anterior cruciate ligament reconstruction: A DTI and TMS study
por: Lepley, Adam S., et al.
Publicado: (2019)

Population pharmacokinetics and model-based dosing evaluation of bedaquiline in multidrug-resistant tuberculosis patients
por: Shao, Ge, et al.
Publicado: (2023)

Population Pharmacokinetics of Glasdegib in Patients With Advanced Hematologic Malignancies and Solid Tumors
por: Lin, Swan, et al.
Publicado: (2019)

Population Pharmacokinetics of Ipilimumab in Combination With Nivolumab in Patients With Advanced Solid Tumors
por: Sanghavi, Kinjal, et al.
Publicado: (2019)

Population pharmacokinetics for oral paclitaxel in patients with advanced/metastatic solid tumors
por: He, Jimmy, et al.
Publicado: (2022)

Exploring Population Pharmacokinetic Modeling with Resampling Visualization
por: Zuo, Fenghua, et al.
Publicado: (2014)

An Approach for Identifiability of Population Pharmacokinetic–Pharmacodynamic Models
por: Shivva, V, et al.
Publicado: (2013)

Individualized Absorption Models in Population Pharmacokinetic Analyses
por: Jaber, Mutaz M., et al.
Publicado: (2020)

A Review of Population Pharmacokinetic Models of Posaconazole
por: Ding, Qin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vscjmlf6spbl5jetan1vsa4gea